hiPSC-Driven Organoid Construction and Application Prospects
Regenerative medicine and dentistry.,
Journal Year:
2025,
Volume and Issue:
unknown, P. 5 - 5
Published: March 21, 2025
Perspective
hiPSC-Driven
Organoid
Construction
and
Application
Prospects
Bangheng
Liu
1,2,
Yulei
Mu
2,3
Dong-An
Wang
1,2,*
1
Department
of
Biomedical
Engineering,
Chinese
University
Hong
Kong,
Sha
Tin,
New
Territories,
Kong
SAR
999077,
China
2
Center
for
Neuromusculoskeletal
Restorative
Medicine,
InnoHK,
HKSTP,
3
City
83
Tat
Chee
Avenue,
Kowloon,
*
Correspondence:
[email protected]
Received:
5
March
2025;
Revised:
19
Accepted:
20
Published:
21
2025
Abstract:
Induced
pluripotent
stem
cell
(iPSC)-derived
organoid
platforms
can
simulate
various
target
tissues
hold
broad
application
prospects
in
personalized
medicine,
disease
modeling,
drug
screening,
organ
transplantation,
understanding
development
mechanisms.
Currently,
the
human
iPSC
(hiPSC)
organoids
is
gradually
shifting
towards
Matrigel-free
scaffold-free
systems,
promoting
precise
control
over
composition
structure
these
systems
establishing
induction
protocols
specialized
organoids.
Researchers
are
also
exploring
construction
multifunctional
with
complex
structures
material
exchange
channels
through
vascularization,
segmented
induction,
assembly
technologies,
though
further
breakthroughs
needed.
In
future,
hiPSC
expected
to
advance
precision
treatment,
high-throughput
module
detection
multi-organ
integration,
automation.
Additionally,
when
combined
large
artificial
intelligence
models,
there
potential
establish
data
medical
platforms,
providing
support
clinical
decision-making.
Moreover,
AI
anticipated
foster
collaboration
rather
than
competition,
coordinated
growth
field.
For
hiPSC-derived
it
crucial
enhance
ethical
review
framework
balance
radical
scientific
exploration
conservative
public
attitudes.
must
optimize
or
develop
new
reduce
genomic
instability
tumorigenic
risks,
while
avoiding
emergence
non-target
cells
insufficient
functional
maturity.
Language: Английский
Neuronally‐Derived Extracellular Vesicles Transforming Growth Factor Beta‐1 Levels in Progressive Supranuclear Palsy
Movement Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 2, 2025
Abstract
Background
Differentiating
progressive
supranuclear
palsy
(PSP)
from
other
parkinsonian
disorders
may
be
challenging.
Objectives
To
investigate
the
role
of
transforming
growth
factor
beta‐1
(TGFβ1)
in
PSP.
Methods
A
total
33
PSP,
39
Parkinson's
disease
(PD),
8
multiple
system
atrophy
(MSA)
patients,
and
50
healthy
controls
(HC)
were
enrolled.
TGFβ1
levels,
including
both
active
inactive
forms
(latency‐associated
peptide
[LAP]‐TGFβ1),
measured
serum,
extracellular
vesicles
(EVs),
neuronally‐derived
EVs
(NDEVs)
using
microfluidic
assays
ELISA.
Results
PSP
patients
exhibited
a
marked
increase
LAP‐TGFβ1
levels
NDEVs,
while
no
differences
observed
across
groups
serum
or
EVs.
Receiver
operating
characteristic
(ROC)
analysis
demonstrated
outstanding
performance
differentiating
non‐PSP
(TGFβ1,
area
under
curve
[AUC]:
0.97;
LAP‐TGFβ1,
AUC:
1.00),
HC,
1.00).
Conclusions
This
study
highlights
NDEVs
as
promising
blood‐based
non‐invasive
biomarkers
for
diagnosis,
paving
way
further
research
on
these
proteins
©
2025
The
Author(s).
Movement
Disorders
published
by
Wiley
Periodicals
LLC
behalf
International
Parkinson
Disorder
Society.
Language: Английский